| Tenofovir-based preexposure prophylaxis for HIV infection among African women JM Marrazzo, G Ramjee, BA Richardson, K Gomez, N Mgodi, G Nair, ... New England Journal of Medicine 372 (6), 509-518, 2015 | 1471 | 2015 |
| Use of a vaginal ring containing dapivirine for HIV-1 prevention in women JM Baeten, T Palanee-Phillips, ER Brown, K Schwartz, LE Soto-Torres, ... New England Journal of Medicine 375 (22), 2121-2132, 2016 | 858 | 2016 |
| Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine UM Parikh, C Dobard, S Sharma, M Cong, H Jia, A Martin, CP Pau, ... Journal of virology 83 (20), 10358-10365, 2009 | 202 | 2009 |
| The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations UM Parikh, L Bacheler, D Koontz, JW Mellors Journal of virology 80 (10), 4971-4977, 2006 | 166 | 2006 |
| Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase UM Parikh, S Zelina, N Sluis-Cremer, JW Mellors Aids 21 (11), 1405-1414, 2007 | 112 | 2007 |
| Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T … MK Hensley, WG Bain, J Jacobs, S Nambulli, U Parikh, A Cillo, B Staines, ... Clinical Infectious Diseases 73 (3), e815-e821, 2021 | 98 | 2021 |
| Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators CS Dezzutti, CW Hendrix, JM Marrazzo, Z Pan, L Wang, N Louissaint, ... PloS one 6 (8), e23136, 2011 | 94 | 2011 |
| Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors N Sluis-Cremer, CW Sheen, S Zelina, PSA Torres, UM Parikh, JW Mellors Antimicrobial agents and chemotherapy 51 (1), 48-53, 2007 | 93 | 2007 |
| Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level UM Parikh, DC Barnas, H Faruki, JW Mellors The Journal of infectious diseases 194 (5), 651-660, 2006 | 89 | 2006 |
| Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? UM Parikh, JW Mellors Current opinion in HIV and AIDS 11 (1), 49-55, 2016 | 84 | 2016 |
| Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study JM Baeten, T Palanee-Phillips, NM Mgodi, AJ Mayo, DW Szydlo, ... The lancet HIV 8 (2), e87-e95, 2021 | 79 | 2021 |
| Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study AN Phillips, V Cambiano, F Nakagawa, P Revill, MR Jordan, TB Hallett, ... The lancet HIV 5 (3), e146-e154, 2018 | 79 | 2018 |
| In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase UM Parikh, DL Koontz, CK Chu, RF Schinazi, JW Mellors Antimicrobial agents and chemotherapy 49 (3), 1139-1144, 2005 | 77 | 2005 |
| Future technologies for monitoring HIV drug resistance and cure UM Parikh, K McCormick, G van Zyl, JW Mellors Current Opinion in HIV and AIDS 12 (2), 182-189, 2017 | 75 | 2017 |
| Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000–2016: a pooled sequence analysis B Chimukangara, RJ Lessells, SY Rhee, J Giandhari, ABM Kharsany, ... EClinicalMedicine 9, 26-34, 2019 | 73 | 2019 |
| Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study LM Noguchi, BA Richardson, JM Baeten, SL Hillier, JE Balkus, ... The lancet HIV 2 (7), e279-e287, 2015 | 60 | 2015 |
| Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors C Dobard, S Sharma, UM Parikh, R West, A Taylor, A Martin, CP Pau, ... Science translational medicine 6 (227), 227ra35-227ra35, 2014 | 53 | 2014 |
| The 3′-azido group is not the primary determinant of 3′-azido-3′-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1 N Sluis-Cremer, D Arion, U Parikh, D Koontz, RF Schinazi, JW Mellors, ... Journal of Biological Chemistry 280 (32), 29047-29052, 2005 | 53 | 2005 |
| Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 vaccination in the … G Haidar, M Agha, A Bilderback, A Lukanski, K Linstrum, R Troyan, ... Clinical Infectious Diseases 75 (1), e630-e644, 2022 | 51 | 2022 |
| Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study G Haidar, M Agha, A Bilderback, A Lukanski, K Linstrum, R Troyan, ... Clinical Infectious Diseases, 2022 | 47 | 2022 |
